Altimmune

ALT · NASDAQ

$2.30+$0.07 (+3.14%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $2.23

Latest news

NewsAug 14, 1:35 PM ET
9 Health Care Stocks Whale Activity In Today’s Session
Press releaseAug 12, 7:30 AM ETGlobe Newswire
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Press releaseAug 3, 8:00 AM ETGlobe Newswire
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
NewsJul 28, 11:08 AM ETVandana Singh
Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
NewsJul 28, 8:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseJul 28, 7:00 AM ETGlobe Newswire
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Press releaseMay 28, 11:00 AM ETGlobe Newswire
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
Press releaseMay 27, 8:00 AM ETGlobe Newswire
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
NewsMay 13, 9:44 AM ET
Altimmune Q1 2026 Earnings Call: Complete Transcript
Press releaseMay 13, 8:30 AM ETGlobe Newswire
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Press releaseMay 13, 7:30 AM ETGlobe Newswire
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Press releaseMay 13, 7:15 AM ETGlobe Newswire
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
NewsApr 23, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsApr 23, 9:30 AM ETNabaparna Bhattacharya
Why Is Altimmune Stock Falling Today?
NewsApr 23, 8:10 AM ETAvi Kapoor
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
NewsApr 23, 8:10 AM ETAvi Kapoor
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
NewsApr 23, 8:07 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsApr 22, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseMar 24, 11:05 AM ETPRNewswire
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
NewsMar 5, 7:28 AM ET
Altimmune: Q4 Earnings Insights
Press releaseJan 29, 1:31 PM ETPRNewswire
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
NewsJan 5, 11:04 AM ETAlex Perry
Why Are Investors Looking At Altimmune Stock?
NewsJan 5, 10:09 AM ETAvi Kapoor
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday
NewsJan 5, 7:44 AM ET
Market-Moving News for January 5th
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsOct 10, 8:02 AM ET
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Press releaseOct 8, 6:10 PM ETGlobe Newswire
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Press releaseOct 7, 7:24 AM ETPRNewswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Press releaseOct 6, 4:49 PM ETGlobe Newswire
Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT
Press releaseOct 6, 1:58 PM ETBusiness Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Press releaseOct 6, 10:09 AM ETGlobe Newswire
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
Press releaseOct 6, 8:45 AM ETPRNewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders
Press releaseOct 5, 11:40 PM ETGlobe Newswire
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Press releaseOct 3, 11:06 AM ETGlobe Newswire
ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm
Press releaseOct 3, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Press releaseOct 3, 9:50 AM ETPRNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Press releaseOct 2, 4:00 PM ETPRNewswire
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Press releaseOct 2, 7:58 AM ETPRNewswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Press releaseOct 1, 4:17 PM ETGlobe Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
Press releaseOct 1, 8:45 AM ETPRNewswire
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Press releaseOct 1, 8:13 AM ETPRNewswire
Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
Press releaseSep 30, 4:44 PM ETPRNewswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Press releaseSep 30, 3:24 PM ETGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors
NewsSep 18, 10:19 AM ETAvi Kapoor
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

9 Health Care Stocks Whale Activity In Today’s Session

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Altimmune Q1 2026 Earnings Call: Complete Transcript

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

Altimmune Announces First Quarter 2026 Financial Results and Business Update

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

Earnings Scheduled For May 13, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Why Is Altimmune Stock Falling Today?

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Altimmune: Q4 Earnings Insights

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Why Are Investors Looking At Altimmune Stock?

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday

Market-Moving News for January 5th

Earnings Scheduled For November 6, 2025

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday